Cullinan Oncology Inc — 貸借対照表 (NASDAQ:CGEM) | MetaTrader

チャート全体を表示

Financials

概要明細書統計

総資産 437.19 M561.12 M484.18 M621.82 M448.37 M 負債合計 11.81 M26.09 M30.29 M31.5 M39.64 M 純資産合計 425.37 M535.03 M453.89 M590.33 M408.73 M 負債および純資産合計 437.19 M561.12 M484.18 M621.82 M448.37 M 有利子負債合計 ——5.59 M2.15 M— 純負債 ——-461.48 M-396.85 M—

ニュース

Stifel、自己免疫疾患の進展を受けてCullinan Oncologyの目標株価を引き上げ

Stifel raises Cullinan Oncology stock price target on autoimmune progress

Cullinan Therapeutics: Thesis Strengthening For T-Cell Engager Specialist (NASDAQ:CGEM)

Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

TheStreet Pro Analysts Say, “Big Tech Names are Anything But Cheap – Buy These 2 Stocks Instead” - TipRanks.com

グッゲンハイムがカリナン・オンコロジー株を「買い」で開始、目標価格30ドル

Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target

Cullinan Therapeutics Stock: Cash-Rich Biotech With Multiple Value Drivers (NASDAQ:CGEM)

Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year?

Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength

カリナン・セラピューティクス、主要自己免疫疾患プログラムのデータ公表を計画

Cullinan Therapeutics plans data readouts for key autoimmune programs